Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021817 | 0.84 | FUCA1 (0.60) | KDM1AFUCA1ACHES1PR1S1PR5 | |
| SCHEMBL13783796 | 0.84 | FUCA1 (0.60) | KDM1AFUCA1ACHES1PR1S1PR5 | |
| SCHEMBL12372536 | 0.84 | FUCA1 (0.60) | KDM1AFUCA1ACHES1PR1S1PR5 | |
| Hydrochloric Acid SCHEMBL15751188 | 0.82 | FUCA1 (0.58) | KDM1AFUCA1ACHES1PR1S1PR5 | |
| SCHEMBL22796181 | 0.81 | ACHE (0.58) | KDM1AFUCA1ACHEHRH4HRH3 | |
| SCHEMBL13291911 | 0.81 | ACHE (0.58) | KDM1AFUCA1ACHEHRH4HRH3 | |
| SCHEMBL6326281 | 0.80 | FUCA1 (0.43) | KDM1AFUCA1ACHEHRH4HRH3 | |
| SCHEMBL5242542 | 0.80 | FUCA1 (0.64) | KDM1AFUCA1ACHEHRH3S1PR1 | |
| SCHEMBL3522693 | 0.79 | FUCA1 (0.55) | FUCA1ACHES1PR1S1PR5LMNA | |
| SCHEMBL3522692 | 0.79 | FUCA1 (0.55) | FUCA1ACHES1PR1S1PR5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | US | disclosed |
| EP-1192156-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | DRD2, ADRA1D, KCND2 | KDM1A 3187/4885FUCA1 4764/4885ACHE 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.